Neuroendocrine and behavioral effects of antisense oligonucleotides

European Journal of Endocrinology

Volumn 137, Issue 4, 1997, Pages 326-335

  Landgraf, Rainer ^a   Naruo, Tetsuro ^b   Vecsernyes, Miklos ^c   Neumann, Inga ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; GENE PRODUCT; NEUROPEPTIDE; RECEPTOR PROTEIN; STEROID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; BEHAVIOR; BLOOD BRAIN BARRIER; CONTROLLED STUDY; FEEDING; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOCOMOTION; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; REVIEW;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; INJECTIONS, INTRAVENTRICULAR; NEUROSECRETORY SYSTEMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0030773342     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1370326     Document Type: Review

References (88)

1. Stein CA. Anti-sense oligodeoxynucleotides - promises and pitfalls. Leukemia 1992 6 967-974.
2. McCarthy MM, Brooks PJ, Pfaus JG, Brown HE, Flanagan LM, Schwartz-Giblin S & Pfaff DW. Antisense oligodeoxynucleotides in behavioral neuroscience. Neuroprotocols 1993 2 67-74.
3. Morris M & Lucion AB. Antisense oligonucleotides in the study of neuroendocrine systems. Journal of Neuroendocrinology 1995 7 493-500.
4. Landgraf R. Antisense targeting in behavioural neuroendocrinology. Journal of Endocrinology 1996 151 333-340.
5. Ogawa S & Pfaff DW. Application of antisense DNA method for the study of molecular bases of brain function and behavior. Behavior Genetics 1996 26 279-292.
6. Tidd DM. Specificity of antisense oligonucleotides. Perspectives in Drug Discovery and Design 1996 4 51-60.
7. Akhtar S & Agrawal S. In vivo studies with antisense oligonucleotides. Trends in Pharmacological Sciences 1997 18 12-18.
8. Neumann I. Antisense oligonucleotides in neuroendocrinology: enthusiasm and frustration. Neurochemistry International 1997 31 363-378.
9. Hunter AJ, Leslie RA, Gloger IS & Lawrence M. Probing the function of novel genes in the nervous system: is antisense the answer? Trends in Neuroscience 1995 18 329-331.
10. Gewirtz AM, Stein CA & Glazer PM. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proceedings of the National Academy of Sciences of the USA 1996 93 3161-3163.
11. Summerton J. Molecular engine for transporting drugs across lipid layers. In: ICB's 2nd International Conference on Advances in the Effective Delivery of Proteins, Peptides and Nucleic Acids. Coronado, 1996.
12. Landgraf R, Gerstberger R, Montkowski A, Probst JC, Wotjak CT, Holsboer F & Engelmann M. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities and anxiety-related behavior in rats. Journal of Neuroscience 1995 15 4250-4258.
13. Russel DS, Widnell KL & Nestler EJ. Antisense oligonucleotides: New tools for the study of brain function. The Neuroscientist 1996 2 79-82.
14. Hebb MO & Robertson HA. End-capped antisense oligodeoxynucleotides effectively inhibit gene expression in vivo and offer a low-toxicity alternative to fully modified phosphorothioate oligodeoxynucleotides. Brain Research 1997 (In Press).
15. Crooke RM. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Design 1991 6 609-646.
16. Akabayashi A, Wahlestedt C, Alexander JT & Leibowitz SF. Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Molecular Brain Research 1994 21 55-61.
17. Meeker R, LeGrand G, Ramirez J, Smith T & Shih Y-H. Antisense vasopressin oligonucleotides: Uptake, turnover, distribution, toxicity and behavioral effects. Journal of Neuroendocrinology 1995 7 419-428.
18. Georgieva J, Heilig M, Nylander I, Herrera-Marschitz M & Terenius L. In vivo antisense inhibition of prodynorphin expression in rat striatum: dose-dependence and sequence specificity. Neuroscience Letters 1995 192 69-71.
19. Skutella T, Montkowski A, Stöhr T, Probst JC, Landgraf R, Holsboer F & Jirikowski GF. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cellular and Molecular Neurobiology 1994 14 579-588.
20. Pellegrini E, Bluet-Pajot MT, Mounier F, Bennett P, Kordon C & Epelbaum J. Central administration of a growth hormone (GH) receptor mRNA antisense increases GH pulsatility and decreases hypothalamic somatostatin expression in rats. Journal of Neuroscience 1996 16 8140-8148.
21. Neumann I, Porter DWF, Landgraf R & Pittman QJ. Rapid effect on suckling of an oxytocin antisense oligonucleotide administered into rat supraoptic nucleus. American Journal of Physiology 1994 267 R852-R858.
22. Hulsey MG, Pless CM, White BD & Martin RJ. ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. Regulatory Peptides 1995 59 207-214.
23. Poulain DA & Theodosis DT. Coupling of electrical activity and hormone release in mammalian neurosecretory neurons. Current Topics in Neuroendocrinology 1988 9 73-104.
24. Neumann I, Kremarik P & Pittman QJ. Acute, sequence-specific effects of oxytocin and vasopressin antisense oligonucleotides on neuronal responses. Neuroscience 1995 69 997-1003.
25. Héléne C & Toulmé J-J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochimica & Biophysica Acta 1990 1049 99-125.
26. Skutella T, Probst JC, Engelmann M, Wotjak CT, Landgraf R & Jirikowski F. Vasopressin antisense oligonucleotide induces temporary diabetes insipidus in rats. Journal of Neuroendocrinology 1994 6 121-125.
27. Scarbrough K, Harney JP, Rosewell KL & Wise PM. Acute effects of antisense antagonism of a single peptide neurotransmitter in the circadian clock. American Journal of Physiology 1996 270 R283-R288.
28. Harney JP, Scarbrough K, Rosewell KL & Wise PM. In vivo antisense antagonism of vasoactive intestinal peptide in the suprachiasmatic nucleus causes aging-like changes in the estradiol-induced luteinizing hormone and prolactin surges. Endocrinology 1996 137 3696-3701.
29. Wotjak CT, Kubota M, Liebsch G, Montkowski A, Holsboer F, Neumann I & Landgraf R. Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: A novel mechanism of regulating adrenocorticotropic hormone secretion? Journal of Neuroscience 1996 16 7725-7732.
30. Ma X-M, Levy A & Lightman S. Rapid changes in heteronuclear RNA for corticotrophin-releasing hormone and arginine vasopressin in response to acute stress. Journal of Endocrinology 1997 152 81-89.
31. Ogilvie KM, Lee S & Rivier C. Role of arginine vasopressin and corticotropin-releasing factor in mediating alcohol-induced adrenocorticotropin and vasopressin secretion in male rats bearing lesions of the paraventricular nuclei. Brain Research 1997 744 83-95.
32. Parkes D, Rivest S, Lee S, Rivier C & Vale W. Corticotropin-releasing factor activates c-fos, NGFI-B, and corticotropin-releasing factor gene expression within the paraventricular nucleus of the rat hypothalamus. Molecular Endocrinology 1993 7 1357-1367.
33. Wotjak CT, Ludwig M & Landgraf, R. Vasopressin facilitates its own release within the rat supraoptic nucleus in vivo. Neuroreport 1994 5 1181-1184.
34. 4) deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor. Life Sciences 1994 55 37-43.
35. Rossi G, Pan YX, Cheng J & Pasternak GW. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sciences 1994 54 375-379.
36. Standifer KM, Chien CC, Wahlestedt C, Brown GP & Pasternak GW. Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron 1994 12 805-810.
37. Chen XH, Adams JU, Geller EB, DeRiel JK, Adler MW & Liu-Chen LY. An antisense oligodeoxynucleotide to mu-opioid receptors inhibits mu-opioid receptor agonist-induced analgesia in rats. European Journal of Pharmacology 1995 275 105-108.
38. Lai J, Bilsky EJ & Porreca F. Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands. Journal of Receptor and Signal Transduction Research 1995 15 643-650.
39. Mizoguchi H, Narita M, Nagase H & Tseng LF. Antisense oligodeoxynucleotide to a delta-opioid receptor blocks the antinociception induced by cold water swimming. Regulatory Peptides 1995 59 255-259.
40. Narita M & Tseng LF. Stimulation of spinal delta-opioid receptors in mice selectively enhances the attenuation of delta-opioid receptor-mediated antinociception by antisense oligodeoxynucleotide. European Journal of Pharmacology 1995 284 185-189.
41. Tseng LF, Narita M & Kampine JP. Pretreatment with beta-endorphin facilitates the attenuation of delta-opioid receptor-mediated antinociception caused by delta-opioid receptor antisense oligodeoxynucleotide. European Journal of Pharmacology 1995 287 169-172.
42. Bilsky EJ, Bernstein RN, Hruby VJ, Rothman RB, Lai J & Porreca F. Characterization of antinociception to opioid receptor-selective agonists after antisense oligodeoxynucleotide-mediated knock-down of opioid receptors in vivo. Journal of Pharmacology and Experimental Therapeutics 1996 277 491-501.
43. Bilsky EJ, Wang T, Lai J & Porreca F. Selective blockade of peripheral delta opioid agonist-induced antinociception by intrathecal administration of delta receptor antisense oligodeoxynucleotide. Neuroscience Letters 1996 220 155-158.
44. Chen XH, Liuchen JY, Tallarida RJ, Geller EB, Deriel JK & Adler MW. Use of a mu-antisense oligodeoxynucleotide as a mu-opioid receptor noncompetitive antagonist in vivo. Neurochemical Research 1996 21 1363-1368.
45. Khasar SG, Gold MS, Dastmalchi S & Levine JD. Selective attenuation of mu-opioid receptor-mediated effects in rat sensory neurons by intrathecal administration of antisense oligodeoxynucleotides. Neuroscience Letters 1996 218 17-20.
46. Lai J, Riedl M, Stone IS, Arvidsson U, Bilsky EJ, Wilcox GL, Eide R & Porreca F. Immunofluorescence analysis of antisense oligodeoxynucleotide-mediated 'knock-down' of the mouse delta opioid receptor in vitro and in vivo. Neuroscience Letters 1996 213 205-208.
47. Aley KO & Levine JD. Multiple receptors involved in peripheral alpha sub(2), mu, and A sub(1) antinociception, tolerance, and withdrawal. Journal of Neuroscience 1997 17 735-744.
48. Vanderah TW, Lai J, Yamamura HI & Porreca F. Antisense oligodeoxynucleotide to the CCK-B receptor produces naltrindole-and (LEU-5) enkephalin antiserum-sensitive enhancement of morphine antinociception. Neuroreport 1994 5 2601-2605.
49. Rossi G, Standifer KM & Pasternak GW. Differential blockade of morphine and morphine-6-beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats. Neuroscience Letters 1995 198 99-102.
50. Sanchez-Blazquez P, Garcia-Espana A & Garzon J. In vivo injection of antisense oligodeoxynucleotides to G-alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists. Journal of Pharmacology and Experimental Therapeutics 1995 275 1590-1596.
51. Raffa RB, Connelly CD, Chambers JR & Stone DJ. Alpha-subunit G-protein antisense oligodeoxynucleotide effects on supraspinal (i.c.v.) alpha sub(2)-adrenoceptor antinociception in mice. Life Sciences 1996 58 PL77-PL80.
52. Hunter JC, Woodburn VL, Durieux C, Pettersson EKE, Poat JA & Hughes J. c-fos antisense oligodeoxynucleotide increases formalin-induced nociception and regulates preprodynorphin expression. Neuroscience 1995 65 485-492.
53. Standaert DG, Testa CM, Rudolf GD & Hollingsworth ZR. Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulation. Journal of Pharmacology and Experimenal Therapeutics 1996 276 342-352.
54. Weiss B, Zhou LW, Zhang SP & Qin ZH. Antisense oligodeoxynucleotide inhibits D-2 dopamine receptor-mediated behavior and D-2 messenger RNA. Neuroscience 1993 55 607-612.
55. Zhang M & Creese I. Antisense oligodeoxynucleotide reduces brain dopamine D-2 receptors: Behavioral correlates. Neuroscience Letters 1993 161 223-226.
56. Sommer W, Bjelke B, Ganten D & Fuxe K. Antisense oligonucleotide to c-fos induces ipsilateral rotational behaviour to d-amphetamine. Neuroreport 1993 5 277-280.
57. Hooper ML, Chiasson BJ & Robertson HA. Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of Fos and produces a behavioral effect. Neuroscience 1994 63 917-924.
58. Korte SM, de Kloet ER, Buwalda B, Bouman SD & Bohus B. Antisense to the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in forced swim test. European Journal of Pharmacology 1996 301 19-25.
59. Mizoguchi H, Narita M, Nagase H, Suzuki T, Quock RM & Tseng LF. Use of antisense oligodeoxynucleotide to determine delta-opioid receptor involvement in (D-Ala-2 (deltorphin II-induced locomotor hyperactivity. Life Sciences 1996 59 PL69-PL73.
60. Spampinato S, Canossa M, Carboni L, Campana G, Leanza G & Ferri S. Inhibition of proopiomelanocortin expression by an oligodeoxynucleotide complementary to β-endorphin mRNA. Proceedings of the National Academy of Sciences of the USA 1994 91 8072-8076.
61. Plata-Salaman CR, Wilson CD, Sonti G, Borkoski JP & French-Mullen JMH. Antisense oligodeoxynucleotides to G-protein alpha-subunit subclasses identify a transductional requirement for the modulation of normal feeding dependent on G-alpha-OA subunit. Molecular Brain Research 1995 33 72-78.
62. Hulsey MG, Pless CM & Martin RJ. ICV administration of anticorticotropin-releasing factor antisense oligonucleotide: effects on feeding behavior and body weight. Regulatory Peptides 1995 59 241-246.
63. Meng H, Wielbo D, Gyurko R & Phillips MI. Antisense oligonucleotide to AT sub(1) receptor mRNA inhibits central angiotensin induced thirst and vasopressin. Regulatory Peptides 1994 54 543-551.
64. Sakai RR, He PF, Yang XD, Ma LY, Guo YF, Reilly JJ, Moga CN & Fluharty SJ. Intracerebroventricular administration of AT-1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. Journal of Neurochemistry 1994 62 2053-2056.
65. McCarthy MM, Kleopoulos SP, Mobbs CV & Pfaff DW. Infusion of antisense oligodeoxynucleotides to the oxytocin receptor in the ventromedial hypothalamus reduces estrogen-induced sexual receptivity and oxytocin receptor binding in the female rat. Neuroendocrinology 1994 59 432-440.
66. Morris M, Li P, Barrett C & Callahan MF. Oxytocin antisense reduces salt intake in the baroreceptor-denervated rat. Regulatory Peptides 1995 59 261-266.
67. Lopez-Valpuesta FJ, Nyce JW, Griffin-Biggs TA, Ice JC & Myers RD. Antisense to NPY-Y1 demonstrates that Y1 receptors in the hypothalamus underlie NPY hypothermia and feeding in rats. Proceedings of the Royal Society of London Series B 1996 263 881-886.
68. Leventhal L, Cole JL, Rossi GC, Pan YX, Pasternak GW & Bodnar RJ. Antisense oligodeoxynucleotides against the MOR-1 clone alter weight and ingestive responses in rats. Brain Research 1996 719 78-84.
69. Pollio G, Xue P, Zanisi M, Nicolin A & Maggi A. Antisense oligonucleotide blocks progesterone-induced lordosis behavior in ovariectomized rats. Molecular Brain Research 1993 19 135-139.
70. Mani SK, Blaustein JD, Allen JMC, Law SW, O'Malley BW & Clark JH. Inhibition of rat sexual behavior by antisense oligonucleotides to the progesterone receptor. Endocrinology 1994 135 1409-1414.
71. Ogawa S, Olazábal UE, Parhar IS & Pfaff DW. Effects of intrahypothalamic administration of antisense DNA for progesterone receptor mRNA on reproductive behavior and progesterone receptor immunoreactivity in female rat. Journal of Neuroscience 1994 14 1766-1774.
72. McCarthy MM, Schlenker EH & Pfaff DW. Enduring consequences of neonatal treatment with antisense oligodeoxynucleotides to estrogen receptor messenger ribonucleic acid on sexual differentiation of rat brain. Endocrinology 1993 133 433-439.
73. Apostolakis EM, Garai J, Clark JH & O'Malley BW. In vivo regulation of central nervous system progesterone receptors: Cocaine induces steroid-dependent behavior through dopamine transporter modulation of D5 receptors in rats. Molecular Endocrinology 1996 10 1595-1604.
74. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regulatory Peptides 1995 59 229-239.
75. Liebsch G, Wotjak CT, Landgraf R & Engelmann M. Septal vasopressin modulates anxiety-related behaviour in rats. Neuroscience Letters 1996 217 101-104.
76. Skutella T, Criswell H, Moy S, Probst JC, Breese GR, Jirikowski GF & Holsboer F. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide induces anxiolytic effects in rat. Neuroreport 1994 5 2181-2185.
77. Moller C, Bing O & Heilig M. C-fos expression in the amygdala: in vivo antisense modulation and role in anxiety. Cellular and Molecular Neurobiology 1994 14 415-423.
78. Wahlestedt C, Merlo Pich E, Koob GF, Yee F & Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993 259 528-531.
79. Castro-Alamancos MA & Torres-Aleman I. Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide. Proceedings of the National Academy of Sciences of the USA 1994 91 10203-10207.
80. Swank MW, Ellis AE & Cochran BN. c-Fos antisense blocks acquisition and extinction of conditioned taste aversion in mice. Neuroreport 1996 7 1866-1870.
81. Szabo G, Nunley KR & Hoffman PL. Antisense oligonucleotide to c-fos blocks the ability of arginine vasopressin to maintain ethanol tolerance. European Journal of Pharmacology 1996 304 67-72.
82. Tischmeyer W, Grimm R, Schicknick H, Brysch W & Schlingensiepen KH. Sequence-specific impairment of learning by c-jun antisense oligonucleotides. Neuroreport 1994 5 1501-1504.
83. Phillips MI, Wielbo D & Gyurko R. Antisense inhibition of hypertension - a new strategy for renin-angiotensin candidate genes. Kidney International 1994 46 1554-1556.
84. Madeddu P, Parpaglia PP, Glorioso N, Chao L & Chao J. Antisense inhibition of the brain kallikrein-kinin system. Hypertension 1996 28 980-987.
85. Wielbo D, Simon A, Phillips MI & Toffolo S. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension 1996 28 147-151.
86. Chen XH, Geller EB, DeRiel JK, Liu-Chen LY & Adler MW. Antisense oligodeoxynucleotides against mu-or kappa-opioid receptors block agonist-induced body temperature changes in rats. Brain Research 1995 688 237-241.
87. Chen XH, Geller EB, DeRiel JK, Liu-Chen LY & Adler MW. Antisense confirmation of mu-opioid and kappa-opioid receptor mediation of morphine effects on body temperature in rats. Drug and Alcohol Dependence 1996 43 119-124.
88. Sakai RR, Ma LY, Zhang DM, McEwen BS & Fluharty SJ. Intracerebral administration of mineralocorticoid receptor antisense oligonucleotides attenuate adrenal steroid-induced salt appetite in rats. Neuroendocrinology 1996 64 425-429.